Background: Congenital cytomegalovirus (CMV) is the most common cause of non-genetic sensorineural hearing loss (SHNL) in children. Only about 10% to 15% of children with congenital CMV is a symptom, and most are not diagnosed at birth. Approximately 7% to 15% of clinically asymptomatic patients may develop complications later, including Sensorineural hearing loss, which is the most common sequelae in patients with clinically asymptomatic. In this study, the hearing status were investigated in children with confirmed CMV infection and newborn hearing screening (NHS) is reviewed to explore the history of hearing loss caused by CMV.
Methods: The medical records of 58 children diagnosed with CMV infection was confirmed in terms of clinical symptoms and signs of CMV infection. Status hearing evaluated by audiological test battery according to age.
Results: A total of 58 children (M: F = 32:26 patient, age of study: mean, 5.62 years, range, 1-10 years) serologically diagnosed with CMV infection (14 patients, 21.1%), or diagnosed through PCR of serum (5, 7.9%) and / or PCR from urine (19, 26.8%). Hearing loss was confirmed in 11 children (19.0%), being bilateral in 6 (54.5%), and unilateral in 5 (45.5%). Note that 7 out of 17 ears with hearing loss passed NHS and diagnosed only after a re-evaluation if CMV infection is identified.
Conclusion: Hearing loss is a serious complication of CMV infection in children. Our results highlight the importance of timely audiological evaluation in children with clinical symptoms of CMV infection even if they pass the NHS.
Audiologic Status of Children with Confirmed Cytomegalovirus Infection: a Case Series
Rare cases of Cytomegalovirus in Gut in immunocompetent hosts With Ischemic Colitis
Cytomegalovirus (CMV) infection is usually seen in individuals with immunosuppressive conditions such as malignancy, HIV / AIDS, and organ transplants, and in patients with chemotherapy or steroids. recurrent disease can occur if the reactivation of the virus because the immune disorder due to factors such as older age or immunosuppressive drugs. CMV is a common, with seroprevalence (CMV IgG) from 40-100% in adults, increases with age. It has been reported that inflammatory bowel disease in remission can be exacerbated by CMV complicate steroid refractory ulcerative colitis or flares. For this reason, steroids should be carefully initiated if a high clinical suspicion for CMV. We report a unique case of CMV colitis is associated with severe ischemic colitis in immunocompetent patients, with a very good response to management with antiviral therapy.
While the cytomegalovirus (CMV) reactivation occurs in critically ill immunocompetent patients and has been associated with worse outcomes, very few cases of CMV reactivation have been reported following the left ventricular assist device (LVAD) implantation. We aimed to evaluate the incidence and risk factors for CMV reactivation following LVAD implantation. A retrospective chart review of patients who have undergone LVAD implantation between July 2004 and December 2018 do. CMV reactivation cases with post-LVAD randomly matched (1: 2) by sex, type of LVAD, and the implant to control utilizing SAS macros.
Description: A sandwich quantitative ELISA assay kit for detection of Human Alpha-2-Microglobulin Like Protein 1 (a2ML1) in samples from serum, plasma, tissue homogenates or other biological fluids.
Human Alpha-2-Microglobulin Like Protein 1 (a2ML1) ELISA Kit
Description: A sandwich quantitative ELISA assay kit for detection of Human Alpha-2-Microglobulin Like Protein 1 (a2ML1) in samples from serum, plasma, tissue homogenates or other biological fluids.
Description: A polyclonal antibody against A2ML1. Recognizes A2ML1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:500-1:5000, IHC:1:20-1:200
Description: A polyclonal antibody against A2ML1. Recognizes A2ML1 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against A2ML1. Recognizes A2ML1 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against A2ML1. Recognizes A2ML1 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Description: pre-made lentiviral particles expressing β-Lactamase gene. A firefly luciferase marker was expressed under RSV promoter. Particles is provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.
Description: Description of target: This gene encodes a member of the alpha-macroglobulin superfamily. The encoded protein is thought to be an N-glycosylated monomeric protein that acts as an inhibitor of several proteases. It has been shown to form covalent interactions with proteases, and has been reported as the p170 antigen recognized by autoantibodies in the autoimmune disease paraneoplastic pemphigus (PNP; PMID:20805888). Mutations in these gene have also been associated with some cases of Noonan syndrome (NS; PMID:24939586) as well as some cases of otitis media (PMID:26121085). Alternative splicing results in multiple transcript variants encoding different isoforms.;Species reactivity: Human;Application: ;Assay info: Quantitative Sandwich ELISA;Sensitivity: < 0.067 ng/mL
Description: Description of target: Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase (By similarity). Displays inhibitory activity against chymotrypsin, papain, thermolysin, subtilisin A and, to a lesser extent, elastase but not trypsin. May play an important role during desquamation by inhibiting extracellular proteases.By similarity;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: < 0.34 ng/mL
Description: Interleukin-3 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 154 amino acids fragment (20-152) and having a total molecular mass of 17.3kDa and fused with a 20 aa N-terminal His tag. ;The IL3 His is purified by proprietary chromatographic techniques.
Fisher’s exact and paired sample t-tests were conducted to evaluate the difference between continuous and categorical variables, respectively. Valid for reactivation implantation post-LVAD counted in cases, and implantation of the appropriate time post-LVAD determined in control patients for comparisonsDays variable reactivation of implantation post-LVAD counted in cases, and implantation of the appropriate time post-LVAD determined in patients controls for comparison variables.
Amber
